ELAC2 polymorphisms and prostate cancer risk: a meta-analysis based on 18 case-control studies

Area of Science:

• Genetics
• Oncology
• Molecular Biology

Background:

• Polymorphisms in the elaC homolog-2 (ELAC2)/HPC2 gene are investigated for their potential role in prostate cancer development.
• Previous studies on the association between ELAC2 polymorphisms and prostate cancer risk have yielded conflicting results.

Purpose of the Study:

• To conduct a comprehensive meta-analysis evaluating the association between ELAC2 Ser217Leu and Ala541Thr polymorphisms and prostate cancer risk.
• To clarify the conflicting findings from individual studies and provide a more robust estimate of the risk associated with these genetic variations.

Main Methods:

• A meta-analysis was performed on data from 18 independent studies.
• The analysis focused on the ELAC2 Ser217Leu and Ala541Thr polymorphisms.
• Statistical methods included odds ratios (OR) and confidence intervals (CI) to assess the association under various genetic models (allele, heterozygote, dominant).

Main Results:

• The ELAC2 Leu217 allele showed a significant association with increased prostate cancer risk (OR=1.13, 95% CI: 1.03-1.24).
• This association was also significant in heterozygote (OR=1.21, 95% CI: 1.07-1.36) and dominant genetic models (OR=1.20, 95% CI: 1.07-1.35).
• The ELAC2 Thr541 allele was also associated with increased prostate cancer risk (OR=1.22, 95% CI: 1.00-0.48).
• Stratified analyses revealed increased risk in Asian and Caucasian populations for Ser217Leu, and in Asian populations for Ala541Thr.

Conclusions:

• The ELAC2 Ser217Leu and Ala541Thr polymorphisms are associated with an increased risk of prostate cancer.
• These genetic variations may function as low-penetrance susceptibility markers for prostate cancer.
• Further research is warranted to elucidate the precise mechanisms underlying this association.